ABBV
AbbVie Inc.Health Caresp500Everything we've seen
- ·May 12, 4:02 PMstreamnews
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
- ·May 12, 4:02 PMstreamnews
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
- ·May 12, 4:02 PMstreamnews
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...
- ·May 12, 4:02 PMstreamnews
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
It's not the news that AbbVie needed, given the challenging year it is having.
- ·May 12, 4:02 PMstreamnews
AbbVie Deserves A Higher Multiple
AbbVie stock looks like a buy: Q1 revenue +12.4% YoY, raised 2026 EPS guidance, and valuation near multiyear lows. See here for more on ABBV.
- ·May 12, 4:02 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
- ·May 12, 4:02 PMstreamnews
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie (ABBV) rated Buy: Q1 2026 revenue +12.4%, raised EPS to $14.18, 3.4% yield, strong pipelineâsee why it fits income & growth.
- ·May 12, 4:02 PMstreamnews
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 20
- ·May 12, 4:02 PMstreamnews
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
- ·May 12, 4:01 PMstreamnews
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
- ·May 12, 4:01 PMstreamnews
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
- ·May 12, 4:01 PMstreamnews
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...
- ·May 12, 4:01 PMstreamnews
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
It's not the news that AbbVie needed, given the challenging year it is having.
- ·May 12, 4:01 PMstreamnews
AbbVie Deserves A Higher Multiple
AbbVie stock looks like a buy: Q1 revenue +12.4% YoY, raised 2026 EPS guidance, and valuation near multiyear lows. See here for more on ABBV.
- ·May 12, 4:01 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
- ·May 12, 4:01 PMstreamnews
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie (ABBV) rated Buy: Q1 2026 revenue +12.4%, raised EPS to $14.18, 3.4% yield, strong pipelineâsee why it fits income & growth.
- ·May 12, 4:01 PMstreamnews
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 20
- ·May 12, 4:01 PMstreamnews
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
- ·May 12, 3:52 PMstreamnews
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
- ·May 12, 3:52 PMstreamnews
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
- ·May 12, 3:52 PMstreamnews
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...
- ·May 12, 3:52 PMstreamnews
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
It's not the news that AbbVie needed, given the challenging year it is having.
- ·May 12, 3:52 PMstreamnews
AbbVie Deserves A Higher Multiple
AbbVie stock looks like a buy: Q1 revenue +12.4% YoY, raised 2026 EPS guidance, and valuation near multiyear lows. See here for more on ABBV.
- ·May 12, 3:52 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
- ·May 12, 3:52 PMstreamnews
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie (ABBV) rated Buy: Q1 2026 revenue +12.4%, raised EPS to $14.18, 3.4% yield, strong pipelineâsee why it fits income & growth.
- ·May 12, 3:52 PMstreamnews
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 20
- ·May 12, 3:52 PMstreamnews
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
- ·May 12, 3:50 PMstreamnews
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
- ·May 12, 3:50 PMstreamnews
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
- ·May 12, 3:50 PMstreamnews
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...
- ·May 12, 3:50 PMstreamnews
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
It's not the news that AbbVie needed, given the challenging year it is having.
- ·May 12, 3:50 PMstreamnews
AbbVie Deserves A Higher Multiple
AbbVie stock looks like a buy: Q1 revenue +12.4% YoY, raised 2026 EPS guidance, and valuation near multiyear lows. See here for more on ABBV.
- ·May 12, 3:50 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
- ·May 12, 3:50 PMstreamnews
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie (ABBV) rated Buy: Q1 2026 revenue +12.4%, raised EPS to $14.18, 3.4% yield, strong pipelineâsee why it fits income & growth.
- ·May 12, 3:50 PMstreamnews
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 20
- ·May 12, 3:50 PMstreamnews
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
- ·May 12, 3:48 PMstreamnews
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
It's not the news that AbbVie needed, given the challenging year it is having.
- ·May 12, 3:48 PMstreamnews
AbbVie Deserves A Higher Multiple
AbbVie stock looks like a buy: Q1 revenue +12.4% YoY, raised 2026 EPS guidance, and valuation near multiyear lows. See here for more on ABBV.
- ·May 12, 3:48 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
- ·May 12, 3:48 PMstreamnews
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie (ABBV) rated Buy: Q1 2026 revenue +12.4%, raised EPS to $14.18, 3.4% yield, strong pipelineâsee why it fits income & growth.
- ·May 12, 3:48 PMstreamnews
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 20
- ·May 12, 3:48 PMstreamnews
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
- !May 12, 3:31 PMsignal
Agent VII — Day Trader — analyze_failed
- ?May 12, 3:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 2.60% today with no identifiable catalyst from recent headlines, suggesting this may be a gap-up or broad market lift rather than a news-driven continuation setup. The macro context (elevated inflation expectations) is not particularly bullish for large-cap pharma like ABBV. With only 30 minutes remaining until the forced close cutoff, there is limited time for meaningful additional price discovery, and late-session mean reversion is a real risk on an unexplained move of this magnitude.
- !May 12, 3:15 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 2.60% today with no identifiable catalyst from recent headlines, suggesting this may be a gap-up or broad market lift rather than a news-driven continuation setup. The macro context (elevated inflation expectations) is not particularly bullish for large-cap pharma like ABBV. With only 30 minutes remaining until the forced close cutoff, there is limited time for meaningful additional price discovery, and late-session mean reversion is a real risk on an unexplained move of this magnitude.
- ?May 12, 3:01 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up 2.73% with no accompanying news headlines to explain the move, making it difficult to attribute the gain to a clear fundamental catalyst that would drive further continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma/biotech name like ABBV. With only 45 minutes remaining until the forced close, there is limited time for meaningful additional upside even if the move were catalyst-driven, and without a clear story the risk of mean reversion or profit-taking into the close is elevated.
- !May 12, 3:01 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV is up 2.73% with no accompanying news headlines to explain the move, making it difficult to attribute the gain to a clear fundamental catalyst that would drive further continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma/biotech name like ABBV. With only 45 minutes remaining until the forced close, there is limited time for meaningful additional upside even if the move were catalyst-driven, and without a clear story the risk of mean reversion or profit-taking into the close is elevated.
- ?May 12, 2:45 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 2.84% with no identifiable news catalyst in the headlines, suggesting the move may be driven by sector rotation, options activity, or thin volume rather than a fundamental event. The macro context (elevated 5Y inflation expectations) is not directly supportive of a healthcare/pharma name like ABBV. With only 60 minutes remaining until the forced close, there is limited time for meaningful continuation, and without a clear catalyst, mean reversion or consolidation is equally plausible.
- !May 12, 2:45 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 2.84% with no identifiable news catalyst in the headlines, suggesting the move may be driven by sector rotation, options activity, or thin volume rather than a fundamental event. The macro context (elevated 5Y inflation expectations) is not directly supportive of a healthcare/pharma name like ABBV. With only 60 minutes remaining until the forced close, there is limited time for meaningful continuation, and without a clear catalyst, mean reversion or consolidation is equally plausible.
- ?May 12, 2:31 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 3.16% today with no identifiable headline catalyst in the last 24 hours, making it difficult to assess whether this move has fundamental support or is driven by technical flows or sector rotation. The macro context flags elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a clear tailwind for healthcare/pharma names like ABBV. With 74 minutes remaining, there is insufficient catalyst clarity to confidently expect continuation, and large gap-up moves without news often see partial mean reversion into the close.
- !May 12, 2:31 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 3.16% today with no identifiable headline catalyst in the last 24 hours, making it difficult to assess whether this move has fundamental support or is driven by technical flows or sector rotation. The macro context flags elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a clear tailwind for healthcare/pharma names like ABBV. With 74 minutes remaining, there is insufficient catalyst clarity to confidently expect continuation, and large gap-up moves without news often see partial mean reversion into the close.
- ?May 12, 2:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up ~2.87% with no identifiable news catalyst in the last 24 hours, suggesting the move may be gap-driven or sector-rotation-related rather than fundamentally supported. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma name like ABBV. With 90 minutes remaining and no clear continuation catalyst, mean reversion or consolidation near current levels is equally plausible as further upside.
- !May 12, 2:15 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up ~2.87% with no identifiable news catalyst in the last 24 hours, suggesting the move may be gap-driven or sector-rotation-related rather than fundamentally supported. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma name like ABBV. With 90 minutes remaining and no clear continuation catalyst, mean reversion or consolidation near current levels is equally plausible as further upside.
- ?May 12, 2:00 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up 3.19% with no identifiable news catalyst or earnings event driving the move, making it difficult to assess whether this is a sustainable directional trend or a gap/spike that may fade. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a healthcare/pharma name. With 105 minutes remaining and no clear fundamental catalyst, mean-reversion pressure after a ~3% intraday move is a real risk, and the lack of headlines leaves the driver ambiguous.
- !May 12, 2:00 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV is up 3.19% with no identifiable news catalyst or earnings event driving the move, making it difficult to assess whether this is a sustainable directional trend or a gap/spike that may fade. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a healthcare/pharma name. With 105 minutes remaining and no clear fundamental catalyst, mean-reversion pressure after a ~3% intraday move is a real risk, and the lack of headlines leaves the driver ambiguous.
- ?May 12, 1:30 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has made a strong 3.62% move with 135 minutes remaining, but there are no identifiable catalysts in recent headlines to explain or sustain the move, suggesting it may be a gap or block-driven event rather than a news-driven continuation. The macro context (elevated 5-year inflation expectations) is not directly supportive of large-cap pharma like ABBV, which is not a typical beneficiary of inflation-reactive sectors. Without a clear fundamental driver, mean-reversion or consolidation into the close is at least as likely as continuation, warranting an uncertain stance.
- !May 12, 1:30 PMsignalseverity 0.04
Agent VII — Day Trader — day_trade_skipped
ABBV has made a strong 3.62% move with 135 minutes remaining, but there are no identifiable catalysts in recent headlines to explain or sustain the move, suggesting it may be a gap or block-driven event rather than a news-driven continuation. The macro context (elevated 5-year inflation expectations) is not directly supportive of large-cap pharma like ABBV, which is not a typical beneficiary of inflation-reactive sectors. Without a clear fundamental driver, mean-reversion or consolidation into the close is at least as likely as continuation, warranting an uncertain stance.
- ?May 12, 1:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up 3.64% with no identifiable catalyst in recent headlines, suggesting this may be a gap-driven move without fresh fundamental support to sustain momentum into the close. The macro context (elevated 5Y inflation expectations) does not specifically benefit healthcare/pharma names like ABBV. With 150 minutes remaining, there is time for the move to extend, but absent a clear news catalyst and given the tendency for large gap-up moves without catalysts to partially fade mid-session, continuation is uncertain.
- !May 12, 1:15 PMsignalseverity 0.04
Agent VII — Day Trader — day_trade_skipped
ABBV is up 3.64% with no identifiable catalyst in recent headlines, suggesting this may be a gap-driven move without fresh fundamental support to sustain momentum into the close. The macro context (elevated 5Y inflation expectations) does not specifically benefit healthcare/pharma names like ABBV. With 150 minutes remaining, there is time for the move to extend, but absent a clear news catalyst and given the tendency for large gap-up moves without catalysts to partially fade mid-session, continuation is uncertain.
- ?May 12, 1:01 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up 4% intraday with no accompanying headlines or identifiable catalyst visible in the data, suggesting this may be a gap or spike move without clear fundamental support for continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a healthcare/pharma name like ABBV. With 165 minutes remaining there is time for continuation, but absent a clear catalyst, mean-reversion or consolidation is equally plausible, keeping conviction low.
- !May 12, 1:01 PMsignalseverity 0.04
Agent VII — Day Trader — day_trade_skipped
ABBV is up 4% intraday with no accompanying headlines or identifiable catalyst visible in the data, suggesting this may be a gap or spike move without clear fundamental support for continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a healthcare/pharma name like ABBV. With 165 minutes remaining there is time for continuation, but absent a clear catalyst, mean-reversion or consolidation is equally plausible, keeping conviction low.
- ?May 12, 12:45 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 3.40% today with no accompanying news catalysts visible, suggesting this could be a gap or technical move without a clear fundamental driver sustaining it. The macro context (elevated 5-year inflation expectations) is more relevant to commodities and TIPS sectors than healthcare/pharma, providing no directional tailwind. With 180 minutes remaining there is time for movement, but absent a catalyst and with a sizable move already priced in, mean reversion risk is meaningful.
- !May 12, 12:45 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 3.40% today with no accompanying news catalysts visible, suggesting this could be a gap or technical move without a clear fundamental driver sustaining it. The macro context (elevated 5-year inflation expectations) is more relevant to commodities and TIPS sectors than healthcare/pharma, providing no directional tailwind. With 180 minutes remaining there is time for movement, but absent a catalyst and with a sizable move already priced in, mean reversion risk is meaningful.
- ?May 12, 12:30 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has already moved 3.19% intraday with no identifiable headline catalyst, suggesting this may be a gap-and-fade or thin-volume spike rather than a news-driven momentum move. The macro context (elevated inflation expectations via T5YIE) is not particularly favorable or unfavorable for a large-cap pharma/biotech like ABBV. With 195 minutes remaining and no clear catalyst to sustain the move, mean reversion is a plausible outcome, making continuation uncertain.
- !May 12, 12:30 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has already moved 3.19% intraday with no identifiable headline catalyst, suggesting this may be a gap-and-fade or thin-volume spike rather than a news-driven momentum move. The macro context (elevated inflation expectations via T5YIE) is not particularly favorable or unfavorable for a large-cap pharma/biotech like ABBV. With 195 minutes remaining and no clear catalyst to sustain the move, mean reversion is a plausible outcome, making continuation uncertain.
- ?May 12, 12:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up ~2.93% with no accompanying headlines or identifiable catalyst, suggesting the move may be driven by broader market sentiment or a gap that has already largely played out. The macro context highlights elevated inflation expectations (T5YIE 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 210 minutes remaining there is time for the move to extend, but without a clear fundamental catalyst, mean reversion or consolidation is equally plausible.
- !May 12, 12:15 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV is up ~2.93% with no accompanying headlines or identifiable catalyst, suggesting the move may be driven by broader market sentiment or a gap that has already largely played out. The macro context highlights elevated inflation expectations (T5YIE 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 210 minutes remaining there is time for the move to extend, but without a clear fundamental catalyst, mean reversion or consolidation is equally plausible.
- ?May 12, 12:00 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 3.27% with no identifiable news catalyst in the recent headlines, suggesting this may be a gap or early-session move without a clear fundamental driver to sustain momentum into the close. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a pharmaceutical stock. With 225 minutes remaining, there is time for either continuation or mean reversion, but the absence of a catalyst makes high-conviction continuation unlikely.
- !May 12, 12:00 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 3.27% with no identifiable news catalyst in the recent headlines, suggesting this may be a gap or early-session move without a clear fundamental driver to sustain momentum into the close. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a pharmaceutical stock. With 225 minutes remaining, there is time for either continuation or mean reversion, but the absence of a catalyst makes high-conviction continuation unlikely.
- ?May 12, 11:45 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 2.86% with no identifiable catalyst from recent headlines, suggesting the move may be driven by broader market sentiment or sector rotation rather than a company-specific event. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not particularly favorable for large-cap pharma/biotech names like ABBV. With 240 minutes remaining and no clear fundamental driver, there is meaningful risk of mean reversion or profit-taking into the close, making continuation uncertain.
- !May 12, 11:45 AMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 2.86% with no identifiable catalyst from recent headlines, suggesting the move may be driven by broader market sentiment or sector rotation rather than a company-specific event. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not particularly favorable for large-cap pharma/biotech names like ABBV. With 240 minutes remaining and no clear fundamental driver, there is meaningful risk of mean reversion or profit-taking into the close, making continuation uncertain.
- ?May 12, 11:30 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 3.43% today with no accompanying news headlines to explain the catalyst, suggesting the move may be driven by sector rotation, options activity, or a gap that lacks fundamental support. With 255 minutes remaining there is time for continuation, but without a clear identifiable catalyst the probability of sustained momentum is moderate at best. The macro context (elevated inflation expectations) is not directly favorable for large-cap pharma, and absent a news driver, mean reversion risk is meaningful after a move of this magnitude.
- !May 12, 11:30 AMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 3.43% today with no accompanying news headlines to explain the catalyst, suggesting the move may be driven by sector rotation, options activity, or a gap that lacks fundamental support. With 255 minutes remaining there is time for continuation, but without a clear identifiable catalyst the probability of sustained momentum is moderate at best. The macro context (elevated inflation expectations) is not directly favorable for large-cap pharma, and absent a news driver, mean reversion risk is meaningful after a move of this magnitude.
- ?May 12, 11:15 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV has moved up 2.85% with no identifiable headline catalyst visible in the recent news feed, suggesting this may be a gap-up or early momentum move without a clear fundamental driver sustaining it. The macro context references elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for large-cap pharma like ABBV. With 270 minutes remaining, there is ample time for either continuation or mean reversion, but the absence of a confirmed catalyst makes high-confidence continuation unlikely.
- !May 12, 11:15 AMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
ABBV has moved up 2.85% with no identifiable headline catalyst visible in the recent news feed, suggesting this may be a gap-up or early momentum move without a clear fundamental driver sustaining it. The macro context references elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for large-cap pharma like ABBV. With 270 minutes remaining, there is ample time for either continuation or mean reversion, but the absence of a confirmed catalyst makes high-confidence continuation unlikely.
- ?May 12, 11:00 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up ~2.49% with no identifiable news catalyst driving the move, making it difficult to assess whether this is a fundamental re-rating or a temporary liquidity-driven spike. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 285 minutes remaining there is time for a continuation, but without a clear catalyst, the move is more likely to partially mean-revert or consolidate near current levels rather than extend meaningfully into the close.
- !May 12, 11:00 AMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
ABBV is up ~2.49% with no identifiable news catalyst driving the move, making it difficult to assess whether this is a fundamental re-rating or a temporary liquidity-driven spike. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 285 minutes remaining there is time for a continuation, but without a clear catalyst, the move is more likely to partially mean-revert or consolidate near current levels rather than extend meaningfully into the close.
- ?May 12, 10:45 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
ABBV is up 2.24% with no identifiable news catalyst or earnings event visible in recent headlines, suggesting the move may be driven by broader market or sector flows rather than a company-specific development. The macro context flags elevated 5-year inflation expectations (T5YIE at 1.9σ above trend), which is more relevant to gold, energy, and TIPS sectors than large-cap pharma like ABBV. With 300 minutes remaining, there is time for either continuation or mean reversion, but the absence of a clear fundamental catalyst makes sustained continuation uncertain.
- !May 12, 10:45 AMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
ABBV is up 2.24% with no identifiable news catalyst or earnings event visible in recent headlines, suggesting the move may be driven by broader market or sector flows rather than a company-specific development. The macro context flags elevated 5-year inflation expectations (T5YIE at 1.9σ above trend), which is more relevant to gold, energy, and TIPS sectors than large-cap pharma like ABBV. With 300 minutes remaining, there is time for either continuation or mean reversion, but the absence of a clear fundamental catalyst makes sustained continuation uncertain.
- ❖May 11, 7:54 AMnewsvia finnhub
AbbVie Stock: Is Wall Street Bullish or Bearish?
AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.
- ❖May 11, 4:45 AMnewsvia finnhub
AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing
AbbVie Q1 2026 beat: Skyrizi growth boosts EPS guidance. Read more here.
- ❖May 10, 2:03 PMnewsvia finnhub
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
- ❖May 10, 1:57 PMnewsvia finnhub
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
- ❖May 9, 10:07 AMnewsvia finnhub
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development. Rob Michael, AbbVie’s chairman and chief executive officer,
- ❖May 9, 9:16 AMnewsvia finnhub
Is It Too Late To Consider AbbVie (ABBV) After Its Recent Share Price Pullback?
This article explains in straightforward terms whether AbbVie at around US$202 per share still offers value or whether most of the opportunity has already been priced in. The stock has recently been mixed, with a 4.1% decline over the last 7 days and a 1.8% decline over the last 30 days. It still shows returns of 12.8% over 1 year, 54.0% over 3 years, and 109.7% over 5 years. Recent coverage has focused on AbbVie's position as a large US pharmaceuticals and biotech company and on how...
- ❖May 8, 2:04 PMnewsvia finnhub
Dividend Champion, Contender, And Challenger Highlights: Week Of May 10
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read this week's list here.
- ❖May 8, 1:31 PMnewsvia finnhub
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
- ❖May 8, 9:25 AMnewsvia finnhub
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Tempus AI, Inc. leverages AI precision medicine, genomic diagnostics, & data licensing to scale growth; key metrics & guidance signal upside. Click for more on TEM.
- ❖May 8, 8:02 AMnewsvia finnhub
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Health officials explored restricting specific antidepressants among SSRI drugs-sources
- ❖May 8, 7:17 AMnewsvia finnhub
AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with […]
- ❖May 7, 5:24 PMnewsvia finnhub
Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
- ❖May 7, 2:55 PMnewsvia finnhub
AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.
Q1 earnings show this Dividend King still looks built for the long term.
- ❖May 7, 2:25 AMnewsvia finnhub
Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...
- ❖May 6, 4:20 PMnewsvia finnhub
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?
They have combined for 118 years of consecutive dividend increases.
- ❖May 6, 10:32 AMnewsvia finnhub
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
- ❖May 6, 10:04 AMnewsvia finnhub
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
- ❖May 6, 8:26 AMnewsvia finnhub
DDW 2026: key readouts from the conference
Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
- ❖May 6, 8:00 AMnewsvia finnhub
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor
MENLO PARK, Calif., May 06, 2026--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor.
- ❖May 6, 8:00 AMnewsvia finnhub
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026. Management will participate in a fireside chat at 1:20 p.m. Central Time.
- ❖May 6, 4:30 AMnewsvia finnhub
Want Reliable Dividend Income in May? These 2 Stocks Deliver
These stocks check off multiple boxes for income investors.
- ❖May 5, 1:38 PMnewsvia finnhub
3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic Value
Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.
- ❖May 5, 12:50 PMnewsvia finnhub
Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating cash flow each month.
- ❖May 5, 11:36 AMnewsvia finnhub
Biotech sector has a strong M&A tailwind, says StemPoint Capital's Michelle Ross
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss the small and mid-cap biotech stocks, the patent cliff coming for the companies in the sector and much more.
- ❖May 5, 11:05 AMnewsvia finnhub
Apple, Amazon, TSMC Top List Of Earnings Triple Plays As Beat-And-Raise Stocks Surge
Apple, Amazon and TSMC are among the largest companies to deliver earnings "triple plays" this season.
- ❖May 5, 9:00 AMnewsvia finnhub
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- ❖May 5, 9:00 AMnewsvia finnhub
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute establishing that the industry's digital future now rests on the 'first mile' of lab data integrity.
- ❖May 5, 8:05 AMnewsvia finnhub
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) in Crohn's disease and ulcerative colitis.
- ❖May 5, 7:38 AMnewsvia finnhub
3 Stocks With Estimated Discounts Up To 44.8% Offering Value Opportunities
The United States market has remained flat over the last week but is up 28% over the past year, with earnings expected to grow by 16% per annum. In such a climate, identifying undervalued stocks that offer significant discounts can present valuable opportunities for investors seeking growth potential.
- ❖May 4, 4:50 PMnewsvia finnhub
AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook
But is the stock a buy on the dip?
- ❖May 4, 4:46 PMnewsvia finnhub
3 of the Best Dividend Stocks to Buy in May 2026
These stocks offer high yields, attractive valuations, significant upside, and can be terrific investments to buy right now.
- ❖May 4, 1:51 PMnewsvia finnhub
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
ABBV jumps 5% after a Q1 beat and higher 2026 guidance, but Skyrizi, Rinvoq and a deep pipeline may matter more for its post-earnings outlook
- ❖May 4, 1:38 PMnewsvia finnhub
MercadoLibre And 2 Other Stocks That May Be Priced Below Their Estimated Value
The market remained flat over the last week, yet it has risen by 28% over the past year with earnings expected to grow by 16% per annum in the coming years. In such an environment, identifying stocks that are potentially undervalued can offer opportunities for investors seeking to capitalize on discrepancies between current prices and estimated intrinsic values.
- ❖May 4, 11:00 AMnewsvia finnhub
FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity
FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., today announced its investment in General Proximity, a San Francisco-based biotechnology company pioneering the next generation of induced proximity medicines.
- ❖May 4, 9:54 AMnewsvia finnhub
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
- ❖May 4, 8:55 AMnewsvia finnhub
10 Years, Zero Regrets: The Dividend Stocks I Keep Buying
Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough environments. The current market volatility and geopolitical unrest have attracted investors to dividend stocks. However, every dividend stock isn’t the same. You might find several high-yield companies, but it makes sense to pick stocks that have consistently ... 10 Years, Zero Regrets: The Dividend Stocks I Keep Buying
- ❖May 4, 8:32 AMnewsvia finnhub
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied
Axsome Therapeutics is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. Read more on AXSM stock here.
- ❖May 4, 7:40 AMnewsvia finnhub
Dividend Income Update Q2, Q3, Q4 2025
The market may move up and down irrationally and seemingly on a whim, while our dividends remain much more stable, reliable and predictable. Read more here.
- ❖May 4, 7:38 AMnewsvia finnhub
Datadog And Two Other Stocks That Could Be Trading Below Fair Value Estimates
Over the last 7 days, the United States market has remained flat, although it has experienced a notable 28% increase over the past year and earnings are forecast to grow by 16% annually. In this context of overall growth, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on potential undervaluation in the market.
- ❖May 4, 7:01 AMnewsvia finnhub
SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with UC, including those in Ontario and Alberta.
- ❖May 4, 6:59 AMnewsvia finnhub
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $236
Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $232 to $236.
- ❖May 4, 3:44 AMnewsvia finnhub
AbbVie Announces Inclusion Of SKYRIZI In Ontario And Alberta Formularies For The Treatment Of Moderately To Severely Active Ulcerative Colitis
To date, SKYRIZI® (risankizumab) has been listed for the treatment of UC on the public drug formularies in Quebec (Médicament d'exception)6, Nova Scotia (Exception Drug Status)7, Non-Insured Health Benefits (NIHB)
- ❖May 2, 8:12 AMnewsvia finnhub
AbbVie Inc. Just Missed Earnings - But Analysts Have Updated Their Models
It's been a good week for AbbVie Inc. ( NYSE:ABBV ) shareholders, because the company has just released its latest...
- ❖May 1, 9:35 AMnewsvia finnhub
10 Health Care Stocks With Whale Alerts In Today's Session
- ❖May 1, 7:44 AMnewsvia finnhub
Guggenheim Reiterates Buy on AbbVie, Maintains $249 Price Target
Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $249 price target.
- ❖May 1, 7:38 AMnewsvia finnhub
Discover 3 Stocks That Might Be Trading Below Estimated Value
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
- ❖May 1, 3:57 AMnewsvia finnhub
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts?
AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on April 27 the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. Management […]
- ❖May 1, 3:55 AMnewsvia finnhub
Netflix, Cisco, Zoom And A Health Care Stock On CNBC's 'Final Trades'
Analysts recommend CSCO, ABBV, NFLX, and ZM as top trades. Cisco and AbbVie report strong earnings, while Netflix and Zoom make positive moves.
- ❖Apr 30, 7:21 PMnewsvia finnhub
Bank of America Upgrades AbbVie (ABBV) on Skyrizi Strength, Lifts PT
AbbVie Inc. (NYSE:ABBV) is included among the 10 Best Large Cap Dividend Growth Stocks to Invest in. On April 30, Bank of America analyst Tim Anderson upgraded AbbVie Inc. (NYSE:ABBV) to Buy from Neutral. It also lifted the price target on the stock to $234 from $226. The firm believes concerns around competitive erosion in […]
- ❖Apr 30, 3:01 PMnewsvia finnhub
Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $265
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $262 to $265.